Cargando…

Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment

Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma. Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome that affects multiple organ systems. We present the case of a 47-year-old African American male with a two-year history of a slowly enlarging right lower back lesion. Upo...

Descripción completa

Detalles Bibliográficos
Autores principales: Eubanks, Bianca N, Tafti, Dawood A, House, Sabrina, Logemann, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489551/
https://www.ncbi.nlm.nih.gov/pubmed/34650853
http://dx.doi.org/10.7759/cureus.17675
_version_ 1784578362217332736
author Eubanks, Bianca N
Tafti, Dawood A
House, Sabrina
Logemann, Nicholas
author_facet Eubanks, Bianca N
Tafti, Dawood A
House, Sabrina
Logemann, Nicholas
author_sort Eubanks, Bianca N
collection PubMed
description Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma. Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome that affects multiple organ systems. We present the case of a 47-year-old African American male with a two-year history of a slowly enlarging right lower back lesion. Upon workup, the 3 × 2 cm mass was biopsied confirming a diagnosis of DFSP. This was identified in concert with axillary freckling, café-au-lait spots, and pedunculated plaques evaluated with biopsy. The findings were consistent with neurofibromas, leading to a new diagnosis of NF1. The patient was definitively treated with wide local excision of the DFSP lesion without tumor recurrence over six years. DFSP has a favorable prognosis when treated with wide local excision and negative surgical margins. However, lesions may recur with inadequate margins. Although deferred in our patient, treatment with imatinib mesylate, a tyrosine kinase inhibitor, may be employed in the setting of advanced disease, metastasis, positive surgical margins, or irresectable locations. Imatinib has also been used to treat NF1. Hence, we posit that the concomitant presentation of these two disease entities in our patient highlights a potentially unique treatment with imatinib mesylate. To our knowledge, this is the second reported case of both entities in the same patient.
format Online
Article
Text
id pubmed-8489551
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-84895512021-10-13 Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment Eubanks, Bianca N Tafti, Dawood A House, Sabrina Logemann, Nicholas Cureus Dermatology Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma. Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome that affects multiple organ systems. We present the case of a 47-year-old African American male with a two-year history of a slowly enlarging right lower back lesion. Upon workup, the 3 × 2 cm mass was biopsied confirming a diagnosis of DFSP. This was identified in concert with axillary freckling, café-au-lait spots, and pedunculated plaques evaluated with biopsy. The findings were consistent with neurofibromas, leading to a new diagnosis of NF1. The patient was definitively treated with wide local excision of the DFSP lesion without tumor recurrence over six years. DFSP has a favorable prognosis when treated with wide local excision and negative surgical margins. However, lesions may recur with inadequate margins. Although deferred in our patient, treatment with imatinib mesylate, a tyrosine kinase inhibitor, may be employed in the setting of advanced disease, metastasis, positive surgical margins, or irresectable locations. Imatinib has also been used to treat NF1. Hence, we posit that the concomitant presentation of these two disease entities in our patient highlights a potentially unique treatment with imatinib mesylate. To our knowledge, this is the second reported case of both entities in the same patient. Cureus 2021-09-03 /pmc/articles/PMC8489551/ /pubmed/34650853 http://dx.doi.org/10.7759/cureus.17675 Text en Copyright © 2021, Eubanks et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Eubanks, Bianca N
Tafti, Dawood A
House, Sabrina
Logemann, Nicholas
Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment
title Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment
title_full Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment
title_fullStr Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment
title_full_unstemmed Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment
title_short Dermatofibrosarcoma Protuberans Presenting in a Patient With Neurofibromatosis Type 1: Potential Implications on Treatment
title_sort dermatofibrosarcoma protuberans presenting in a patient with neurofibromatosis type 1: potential implications on treatment
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489551/
https://www.ncbi.nlm.nih.gov/pubmed/34650853
http://dx.doi.org/10.7759/cureus.17675
work_keys_str_mv AT eubanksbiancan dermatofibrosarcomaprotuberanspresentinginapatientwithneurofibromatosistype1potentialimplicationsontreatment
AT taftidawooda dermatofibrosarcomaprotuberanspresentinginapatientwithneurofibromatosistype1potentialimplicationsontreatment
AT housesabrina dermatofibrosarcomaprotuberanspresentinginapatientwithneurofibromatosistype1potentialimplicationsontreatment
AT logemannnicholas dermatofibrosarcomaprotuberanspresentinginapatientwithneurofibromatosistype1potentialimplicationsontreatment